EXCLUSIVE: Vivani Medical Subdermal Semaglutide Implant Shows 20% Weight Loss In Animal Study, With Potential For Once-Yearly Dosing

Zinger Key Points

Single dose of Vivani’s NPM-139 semaglutide implant led to nearly 20% weight loss in rats, suggesting once- or twice-yearly dosing.
NPM-139 showed steady semaglutide release with potential for once-yearly administration, supported by over a year of in vitro stability data
Pelosi’s latest AI pick skyrocketed 169% in just one month. Click here to discover the next stock our government trade tracker is spotlighting—before it takes off.

Vivani Medical, Inc. VANI, on Wednesday, released preclinical data for NPM-139, its subdermal semaglutide implant under development for chronic weight management in obese and overweight individuals.

Semaglutide is the active ingredient in Novo Nordisk A/S’ NVO Ozempic and Wegovy, which are available for diabetes and weight loss.

In an ongoing study in healthy rats, a single administration of the semaglutide implant NPM-139 resulted in body weights nearly 20% lower than a sham implant control group throughout a 91-day treatment period.

NPM-139 treatment resulted in nearly 20% placebo-adjusted weight loss from a single administration with expected once or twice-yearly dosing.

Also Read: EXCLUSIVE: Vivani Medical To Spin Off Cortigent Neurostimulation Business To Create Better Focus On Individual Entities And Shareholder Value

Like NPM-119 and NPM-115, NPM-139 has demonstrated smooth, non-fluctuating in vivo release. The study demonstrated continuous and steady semaglutide exposure throughout the study period.

NPM-139 has previously demonstrated therapeutic semaglutide exposure levels in pharmacokinetic data over six months in healthy rats.

In-vitro chemical and physical stability measurements for durations exceeding one year indicate the potential for once-yearly administration of NPM-139.

The ongoing NPM-115 clinical study, LIBERATE-1, remains on track to produce top-line data by mid-2025.

Earlier this month, Vivani Medical announced the administration of its first GLP-1 (exenatide, NPM-115) implant in the LIBERATE-1 trial in Australia.

Vivani’s lead program, NPM-115, utilizes a miniature, six-month, subdermal, GLP-1 (exenatide) implant under development for chronic weight management in obese or overweight individuals.

Last year, Vivani Medical released preclinical data on weight loss effects for NPM-115.

In a study in high-fat diet-induced obese mice, NPM-115 generated weight loss of approximately 20% compared to a sham implant control after a 28-day treatment duration.

Price Action: VANI stock closed at $1.10 on Tuesday.

Read Next: